Article in Journal of immunology (Baltimore, Md. : 1950), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
5 citing papers in PubMed, 7 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
5 authors at 1 institution in 1 country.
Trey E GilpinDepartment of Pathology and Laboratory Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI; and.
Fruzsina R WalterDepartment of Pathology and Laboratory Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI; and.ORCID 0000-0001-8145-2823
Melinda HerbathDepartment of Pathology and Laboratory Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI; and.
Matyas SandorDepartment of Pathology and Laboratory Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI; and.
Zsuzsanna FabryDepartment of Pathology and Laboratory Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI; and zfabry@wisc.edu.
University of Wisconsin–Madison · US
Funding
UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6M
Neuroinflammation-induced lymphangiogenesis in the CNSR01NS108497 · NINDS · UNIVERSITY OF WISCONSIN-MADISON · PI FABRY, ZSUZSANNA · 2018 to 2022
$1.9M
Graduate Training In Cellular And Molecular Pathogenesis Of Human DiseasesT32GM081061 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI FABRY, ZSUZSANNA · 2010 to 2019
$1.8M
CNS TuberculosisR01NS076946 · NINDS · UNIVERSITY OF WISCONSIN-MADISON · PI FABRY, ZSUZSANNA · 2012 to 2016
$1.7M
Innate immunity of granulomatous inflammation: the role of VEGFR01HL128778 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI SANDOR, MATYAS · 2016 to 2019
$1.5M
Mycobacterial antigen compartmentalization &immunityR01AI046430 · NIAID · UNIVERSITY OF WISCONSIN MADISON · PI SANDOR, MATYAS · 2002 to 2005
$1.4M
Traffic from chronic mycobacterium induced granulomasR21AI072638 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI SANDOR, MATYAS · 2008 to 2009
$401k
Innate immunity of granulomatous inflammation: the role of VEGFR56HL128778 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI SANDOR, MATYAS · 2015 to 2015
CNS tuberculosis (CNSTB) is the most severe manifestation of extrapulmonary tuberculosis infection, but the mechanism of how mycobacteria cross the blood-brain barrier (BBB) is not well understood. In this study, we report a novel murine in vitro BBB model combining primary brain endothelial cells,
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.